Multiple Myeloma
Item
1. subject previously diagnosed with multiple myeloma based either on the standard or the international myeloma foundation (imf) diagnostic criteria as defined in appendix a
boolean
C0026764 (UMLS CUI [1])
Recurrent disease | Refractory Disease | Status post Line of Therapy Quantity
Item
2. subjects must have relapsed or relapsed/refractory disease after at least 2 prior lines of therapy as defined in appendix d
boolean
C0277556 (UMLS CUI [1])
C1514815 (UMLS CUI [2])
C0231290 (UMLS CUI [3,1])
C4524693 (UMLS CUI [3,2])
C1265611 (UMLS CUI [3,3])
Monoclonal Protein Measurement Serum | Monoclonal free light chain present Urine protein electrophoresis | Immunoglobulin Light Chains Measurable | Free Immunoglobulin Light Chain Assay | Plasmacytoma Measurable
Item
3. monoclonal protein in the serum of equal to or greater than 1 gm/dl or monoclonal light chain in the urine protein electrophoresis of equal to or greater than 200 mg/24 hours, or measurable light chains by free light chain assay of equal to or greater than 10 mg/dl, or measurable plasmacytoma
boolean
C2984963 (UMLS CUI [1,1])
C0229671 (UMLS CUI [1,2])
C1532998 (UMLS CUI [2,1])
C0201721 (UMLS CUI [2,2])
C0021038 (UMLS CUI [3,1])
C1513040 (UMLS CUI [3,2])
C0806492 (UMLS CUI [4,1])
C1510438 (UMLS CUI [4,2])
C0032131 (UMLS CUI [5,1])
C1513040 (UMLS CUI [5,2])
Age
Item
4. age ≥ 18 years at the time of signing the informed consent form
boolean
C0001779 (UMLS CUI [1])
ECOG performance status
Item
5. ecog performance status < 2
boolean
C1520224 (UMLS CUI [1])
Life Expectancy
Item
6. life expectancy > 3 months
boolean
C0023671 (UMLS CUI [1])
Laboratory Results
Item
7. subjects must have the following laboratory parameters:
boolean
C1254595 (UMLS CUI [1])
Hemoglobin measurement
Item
hemoglobin > 8.0 gm/dl
boolean
C0518015 (UMLS CUI [1])
Absolute neutrophil count
Item
absolute neutrophil count (anc) ≥1000 cells/mm3
boolean
C0948762 (UMLS CUI [1])
Platelet Count measurement
Item
platelets count ≥ 50,000/mm3
boolean
C0032181 (UMLS CUI [1])
Aspartate aminotransferase measurement
Item
serum sgot/ast <3.0 x institutional upper limits of normal (uln)
boolean
C0201899 (UMLS CUI [1])
Alanine aminotransferase measurement
Item
serum sgpt/alt <3.0 x institutional upper limits of normal (uln)
boolean
C0201836 (UMLS CUI [1])
Creatinine measurement, serum
Item
serum creatinine <2.5mg/dl
boolean
C0201976 (UMLS CUI [1])
Serum total bilirubin measurement
Item
serum total bilirubin <1.5 x institutional upper limits of normal (uln)
boolean
C1278039 (UMLS CUI [1])
Childbearing Potential Serum pregnancy test negative | Hysterectomy Absent | Postmenopausal state Absent | Normal menstruation | Childbearing Potential Sexually active Contraceptive methods | Gender Sexually active Contraceptive methods | Hormonal contraception | Contraception, Barrier | Sexual Abstinence | Exception Sterilization | Informed Consent
Item
8. woman of childbearing potential [defined as a sexually mature woman who has not undergone hysterectomy or who has not been naturally postmenopausal for at least 24 consecutive months (i.e. who has had menses any time in the preceding 24 consecutive months) with a negative serum pregnancy test. in addition, all sexually active woman of childbearing potential and men agreeing to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, during the duration of study participation and for at least 4 weeks after withdrawal from the study, unless they are surgically sterilised
boolean
C3831118 (UMLS CUI [1,1])
C0430061 (UMLS CUI [1,2])
C0020699 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0232970 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
C0559892 (UMLS CUI [4])
C3831118 (UMLS CUI [5,1])
C0241028 (UMLS CUI [5,2])
C0700589 (UMLS CUI [5,3])
C0079399 (UMLS CUI [6,1])
C0241028 (UMLS CUI [6,2])
C0700589 (UMLS CUI [6,3])
C2985296 (UMLS CUI [7])
C0004764 (UMLS CUI [8])
C0036899 (UMLS CUI [9])
C1705847 (UMLS CUI [10,1])
C0038288 (UMLS CUI [10,2])
Informed Consent
Item
9. ability to understand and the willingness to sign a written informed consent document
boolean
C0021430 (UMLS CUI [1])
Therapeutic radiology procedure | Immunotherapy | Chemotherapy | Biological Factors | G-CSF | Investigational New Drugs Adverse effects Recovery Lacking
Item
1. subjects having received radiotherapy, immunotherapy, chemotherapy and or biological agents like g-csf in the 2 weeks prior to day 1 of study drug administration and have not recovered completely from the side effects of the earlier investigational agent
boolean
C1522449 (UMLS CUI [1])
C0021083 (UMLS CUI [2])
C0392920 (UMLS CUI [3])
C0005515 (UMLS CUI [4])
C0079459 (UMLS CUI [5])
C0013230 (UMLS CUI [6,1])
C0879626 (UMLS CUI [6,2])
C2004454 (UMLS CUI [6,3])
C0332268 (UMLS CUI [6,4])
Investigational New Drugs Other
Item
2. subjects having received any other investigational agents within 2 weeks prior to the date of enrolment
boolean
C0013230 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
Allergic Reaction Compound P276-00 Similar
Item
3. history of allergic reactions attributed to compounds of similar chemical composition to p276-00
boolean
C1527304 (UMLS CUI [1,1])
C1706082 (UMLS CUI [1,2])
C1832023 (UMLS CUI [1,3])
C2348205 (UMLS CUI [1,4])
Myocardial Infarction | Cardiac dysfunction Uncontrolled
Item
4. subjects with a history of myocardial infarction or uncontrolled cardiac dysfunction during the previous 6 months
boolean
C0027051 (UMLS CUI [1])
C3277906 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
Malignant Neoplasms | Exception Basal cell carcinoma Treated | Exception Squamous cell carcinoma of skin Treated | Exception Carcinoma in situ of uterine cervix Treated | Exception Carcinoma in situ of female breast Treated | Exception Carcinoma in situ of prostate Treated | Exception Disease Free of
Item
5. prior malignancy (within the last 3 years) except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, in situ breast cancer, in situ prostate cancer or any other cancer for which the subject has been disease-free for at least 3 years
boolean
C0006826 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0007117 (UMLS CUI [2,2])
C1522326 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0553723 (UMLS CUI [3,2])
C1522326 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C0851140 (UMLS CUI [4,2])
C1522326 (UMLS CUI [4,3])
C1705847 (UMLS CUI [5,1])
C0686288 (UMLS CUI [5,2])
C1522326 (UMLS CUI [5,3])
C1705847 (UMLS CUI [6,1])
C0154088 (UMLS CUI [6,2])
C1522326 (UMLS CUI [6,3])
C1705847 (UMLS CUI [7,1])
C0012634 (UMLS CUI [7,2])
C0332296 (UMLS CUI [7,3])
Comorbidity Uncontrolled | Communicable Disease | Symptomatic congestive heart failure | Cardiac ejection fraction | Angina, Unstable | Cardiac Arrhythmia | Mental disorders Protocol Compliance Limited | Social situation Protocol Compliance Limited | Pregnancy | Breast Feeding | HIV Seropositivity | Pharmaceutical Preparations Causing Prolonged QT interval | Pharmaceutical Preparations Causing Prolonged QTc interval | Pharmaceutical Preparations Causing Torsades de Pointes | Condition Study Subject Participation Status At risk | Laboratory test result abnormal Study Subject Participation Status At risk
Item
6. subjects with uncontrolled inter-current illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, known cardiac ejection fraction <40%, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
boolean
C0009488 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0009450 (UMLS CUI [2])
C0742758 (UMLS CUI [3])
C0232174 (UMLS CUI [4])
C0002965 (UMLS CUI [5])
C0003811 (UMLS CUI [6])
C0004936 (UMLS CUI [7,1])
C0525058 (UMLS CUI [7,2])
C0439801 (UMLS CUI [7,3])
C0748872 (UMLS CUI [8,1])
C0525058 (UMLS CUI [8,2])
C0439801 (UMLS CUI [8,3])
Pregnancy | Breast Feeding
Item
7. women who are pregnant or nursing
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
HIV Seropositivity
Item
8. subjects known to be seropositive for the human immunodeficiency virus
boolean
C0019699 (UMLS CUI [1])
Pharmaceutical Preparations Causing Prolonged QT interval | Pharmaceutical Preparations Causing Prolonged QTc interval | Pharmaceutical Preparations Causing Torsades de Pointes
Item
9. subjects requiring the use of concomitant medications that prolong the qt/qtc interval and/or are known to cause torsades de pointes (tdp)
boolean
C0013227 (UMLS CUI [1,1])
C0678227 (UMLS CUI [1,2])
C0151878 (UMLS CUI [1,3])
C0013227 (UMLS CUI [2,1])
C0678227 (UMLS CUI [2,2])
C1560305 (UMLS CUI [2,3])
C0013227 (UMLS CUI [3,1])
C0678227 (UMLS CUI [3,2])
C0040479 (UMLS CUI [3,3])
Condition Study Subject Participation Status At risk | Laboratory test result abnormal Study Subject Participation Status At risk
Item
10. any condition, including laboratory abnormalities, that in the opinion of the investigator places the subject at unacceptable risk if he/she were to participate in the study
boolean
C0348080 (UMLS CUI [1,1])
C2348568 (UMLS CUI [1,2])
C1444641 (UMLS CUI [1,3])
C0438215 (UMLS CUI [2,1])
C2348568 (UMLS CUI [2,2])
C1444641 (UMLS CUI [2,3])